Spiriva capsules contain 18 mcg of tiotropium and are light green ... other than inhaled anticholinergics. The coprimary endpoints were the proportion of patients with COPD exacerbation and ...

Companies like AstraZeneca and GSK, which have high-revenue-generating inhalers for asthma and chronic obstructive pulmonary disorder ... in what it calls ‘green prescribing.’ ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium ... patients with moderate to very-severe COPD. AstraZeneca and Ionis add an EU green light to earlier approvals in the US and ...

A review of the literature was conducted to examine the clinical effectiveness of inhaled GSH as a treatment for various pulmonary diseases and respiratory-related conditions. This report also ...

Flare-ups in chronic obstructive pulmonary disease, the UK’s fourth leading cause of death, can be reduced by 20% by a combined triple inhaler, according to the results of a trial of more than 2,000 ...

Various types of inhalers, including short- and long-lasting options, are available for managing chronic obstructive pulmonary disease (COPD). A person can get a COPD inhaler through Medicare Part ...

Compared with control patients, invited patients spent less out-of-pocket. Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for ...